
Aeterna Zentaris AEZS
Annual report 2024
added 03-21-2026
Aeterna Zentaris Depreciation & Amortization 2011-2026 | AEZS
Annual Depreciation & Amortization Aeterna Zentaris
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 58 K | 94 K | 280 K | 341 K | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 341 K | 58 K | 193 K |
Depreciation & Amortization of other stocks in the Biotechnology industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Amgen
AMGN
|
5.17 B | $ 350.62 | 0.81 % | $ 189 B | ||
|
Heron Therapeutics
HRTX
|
2.31 M | $ 0.8 | 2.35 % | $ 133 M | ||
|
Altimmune
ALT
|
112 K | $ 3.46 | 3.44 % | $ 305 M | ||
|
I-Mab
IMAB
|
23.9 M | - | - | $ 866 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.51 M | - | - | $ 26.5 M | ||
|
ARCA biopharma
ABIO
|
27 K | - | 1052.0 % | $ 415 M | ||
|
Incyte Corporation
INCY
|
93.3 M | $ 90.74 | -0.04 % | $ 17.7 B | ||
|
AgeX Therapeutics
AGE
|
131 K | - | -10.17 % | $ 12.2 K | ||
|
Acorda Therapeutics
ACOR
|
31.7 M | - | -24.86 % | $ 820 K | ||
|
Albireo Pharma
ALBO
|
274 K | - | -0.23 % | $ 916 M | ||
|
Inovio Pharmaceuticals
INO
|
2.62 M | $ 1.62 | 2.22 % | $ 35.9 M | ||
|
Aileron Therapeutics
ALRN
|
63 K | - | 10.36 % | $ 9.8 M | ||
|
Acasti Pharma
ACST
|
7 K | - | 4.01 % | $ 150 M | ||
|
Adverum Biotechnologies
ADVM
|
3.65 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
66 K | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
369 K | - | -9.65 % | $ 45.9 M | ||
|
Ayala Pharmaceuticals
AYLA
|
162 K | - | - | $ 7.46 M | ||
|
Cullinan Management
CGEM
|
311 K | $ 12.92 | 1.41 % | $ 778 M | ||
|
Atreca
BCEL
|
5.46 M | - | -11.76 % | $ 5.79 M | ||
|
BioDelivery Sciences International
BDSI
|
140 K | - | -4.8 % | $ 255 M | ||
|
BeiGene, Ltd.
BGNE
|
142 M | - | 0.49 % | $ 251 B | ||
|
KalVista Pharmaceuticals
KALV
|
941 K | $ 16.76 | -1.41 % | $ 832 M | ||
|
Calithera Biosciences
CALA
|
300 K | - | -10.95 % | $ 876 K | ||
|
Cara Therapeutics
CARA
|
259 K | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
3.14 M | - | - | $ 3.74 B | ||
|
Karyopharm Therapeutics
KPTI
|
340 K | $ 7.06 | -7.47 % | $ 860 K | ||
|
Clovis Oncology
CLVS
|
8.5 M | - | -7.23 % | $ 13 M | ||
|
Keros Therapeutics
KROS
|
1.51 M | $ 11.27 | 2.83 % | $ 419 M | ||
|
Aeglea BioTherapeutics
AGLE
|
744 K | - | - | $ 1.01 B | ||
|
Denali Therapeutics
DNLI
|
7.8 M | $ 21.23 | 5.26 % | $ 3.49 B | ||
|
Longeveron
LGVN
|
800 K | $ 0.95 | -3.52 % | $ 16.7 B | ||
|
Akero Therapeutics
AKRO
|
18 K | - | - | $ 3.67 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
1.4 M | $ 4.3 | 1.3 % | $ 714 M | ||
|
Akouos
AKUS
|
2.49 M | - | 0.23 % | $ 488 M | ||
|
AIkido Pharma
AIKI
|
105 K | - | 1.93 % | $ 17.4 M |